Junedh Amrute

Nov 13, 2024 | medrxiv.org | Junedh Amrute |Paul Lee |Ittai Eres |Andrea Bredemeyer

JA, IE, TY, DL, YHH, SH, SJ, CML, and BA were or are employed by Amgen. This work was supported by National Institutes of Health grantsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Oct 23, 2024 | nature.com | Junedh Amrute |Tracy M. Yamawaki |Sikander Hayat |Andrea Bredemeyer |In-Hyuk Jung |Andrew Koenig | +9 more

AbstractInflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2. However, the molecular mechanisms driving immune–fibroblast cell communication in human cardiac disease remain unexplored and there are at present no approved treatments that directly target cardiac fibrosis3,4. Here we performed multiomic single-cell gene expression, epitope mapping and chromatin accessibility profiling in 45 healthy donor, acutely infarcted and chronically failing human hearts.

Sep 26, 2024 | biorxiv.org | Junedh Amrute |Attila Kovacs |Abhinav Diwan |David Williams

AbstractBackground: Although the ability of the heart to adapt to environmental stress has been studied extensively, the molecular and cellular mechanisms responsible for cardioprotection are not yet fully understood. Methods: We administered Toll-like receptor (TLR) agonists or a diluent to wild-type mice and assessed their potential to induce cardiac protection against injury from a high intraperitoneal dose of isoproterenol (ISO) administered 7 days later.